C9854
Monoclonal Anti-CD86 antibody produced in mouse
~0.5 mg/mL, clone B72-H2, purified immunoglobulin, buffered aqueous solution
Synonym(s):
Anti-B7-2
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12352203
MDL number:
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
clone
B72-H2, monoclonal
form
buffered aqueous solution
mol wt
antigen ~75 kDa
species reactivity
human
concentration
~0.5 mg/mL
technique(s)
flow cytometry: suitable, immunohistochemistry (frozen sections): suitable
isotype
IgG2a
shipped in
wet ice
Gene Information
human ... CD86(942)
General description
CD86 is one of two ligands (the other is CD80) for CD152 (CTLA-4) and CD28. CD86 acts as co-stimulatory molecule in eliciting T cell help during antigen presentation. Antigen presentation in the absence of sufficient co-stimulation involving CD86/CD80 can induce tolerance. CD86 appears to play a role distinct from CD80 in T helper cell differentiation. CD86 is rapidly induced on the surface of activated B cells, T cells or monocytes and is expressed at high levels on dendritic cells. It is also found on malignant Hodgkin and Reed-Sternberg (H-RS) cells in Hodgkin′s disease.
Immunogen
recombinant extracellular domain of human CD86.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 0.08% sodium azide.
Preparation Note
Prepared from tissue culture supernatant, purified using protein G.
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Laura J Vella et al.
Cancer immunology research, 2(4), 351-360 (2014-04-26)
Combination therapy with BRAF and MEK inhibition is currently in clinical development for the treatment of BRAF-mutated malignant melanoma. BRAF inhibitors are associated with enhanced antigen-specific T-lymphocyte recognition in vivo. Consequently, BRAF inhibition has been proposed as proimmunogenic and there
David G Hancock et al.
PloS one, 9(6), e100613-e100613 (2014-06-21)
Dendritic cells (DCs) are critical for regulating CD4 and CD8 T cell immunity, controlling Th1, Th2, and Th17 commitment, generating inducible Tregs, and mediating tolerance. It is believed that distinct DC subsets have evolved to control these different immune outcomes.
Yuanji Ma et al.
Oxidative medicine and cellular longevity, 2014, 148798-148798 (2014-08-12)
Dendritic cells (DCs), which are highly proficient antigen-presenting cells, play a complex role in both the initiation and progression of atherosclerosis. We tested the hypothesis that the anti-inflammatory and antioxidant effects of atorvastatin may be partly mediated by the phosphatidylinositol
Kazuyuki Kasahara et al.
Journal of the American Heart Association, 3(2), e000719-e000719 (2014-04-24)
Accumulating evidence suggests that the balance between pathogenic effector T cells (Teffs) and regulatory T cells (Tregs) may be important for controlling atherosclerotic disease. We hypothesized that a combination therapy with anti-CD3 antibody (CD3-Ab) and IL-2/anti-IL-2 monoclonal antibody complex (IL-2
Yuling Zhao et al.
PloS one, 9(9), e106867-e106867 (2014-09-18)
The pathobiology of Parkinson's disease (PD) is associated with the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) projecting to the striatum. Currently, there are no treatments that can halt or reverse the course of PD; only
Related Content
Datasheet
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service